﻿<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Explor Med</journal-id>
<journal-id journal-id-type="publisher-id">EM</journal-id>
<journal-title-group>
<journal-title>Exploration of Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2692-3106</issn>
<publisher>
<publisher-name>Open Exploration Publishing</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.37349/emed.2026.1001424</article-id>
<article-id pub-id-type="manuscript">1001424</article-id>
<article-categories>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Suspected triple co-infection with SARS-CoV-2, <italic>Legionella pneumophila</italic>, and <italic>Streptococcus pneumoniae</italic> after hot-spring travel: a case report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hirose</surname>
<given-names>Ryutaro</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I1" />
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9781-258X</contrib-id>
<name>
<surname>Takahashi</surname>
<given-names>Hidenori</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I1" />
<xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yasuda</surname>
<given-names>Takumi</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1" />
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taguchi</surname>
<given-names>Kota</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1" />
</contrib>
<contrib contrib-type="author">
<name>
<surname>Furukawa</surname>
<given-names>Kanako</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1" />
</contrib>
<contrib contrib-type="author">
<name>
<surname>Satake</surname>
<given-names>Yugo</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1" />
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nagamatsu</surname>
<given-names>Hiroki</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1" />
</contrib>
<contrib contrib-type="author">
<name>
<surname>Toba</surname>
<given-names>Naoya</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1" />
</contrib>
<contrib contrib-type="author">
<name>
<surname>Toyama-Kousaka</surname>
<given-names>Mio</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1" />
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0922-8656</contrib-id>
<name>
<surname>Ota</surname>
<given-names>Shinichiro</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1" />
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morikawa</surname>
<given-names>Miwa</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1" />
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8101-8653</contrib-id>
<name>
<surname>Shinkai</surname>
<given-names>Masaharu</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1" />
</contrib>
<contrib contrib-type="editor">
<name>
<surname>Spagnolo</surname>
<given-names>Anna Maria</given-names>
</name>
<role>Academic Editor</role>
<aff>University of Genova, Italy</aff>
</contrib>
</contrib-group>
<aff id="I1">Respiratory Disease Center, Tokyo Shinagawa Hospital, Tokyo 140-8522, Japan</aff>
<author-notes>
<corresp id="cor1">
<bold>
<sup>*</sup>Correspondence:</bold> Hidenori Takahashi, Respiratory Disease Center, Tokyo Shinagawa Hospital, Tokyo 140-8522, Japan. <email>hidenori.tsh@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2026</year>
</pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>08</month>
<year>2026</year>
</pub-date>
<volume>7</volume>
<elocation-id>1001424</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>05</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>07</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2026.</copyright-statement>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<p id="absp-1">Bacterial co-infection in patients with coronavirus disease 2019 (COVID-19) can complicate diagnosis because of overlapping clinicoradiologic findings among pathogens. We report a case of suspected triple co-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), <italic>Legionella pneumophila</italic> (<italic>L. pneumophila</italic>), and <italic>Streptococcus pneumoniae</italic> (<italic>S. pneumoniae</italic>) after hot-spring travel in a post-splenectomy patient. A man in his 70s with a history of subtotal esophagectomy and concomitant splenectomy for esophageal cancer was admitted with fever, worsening productive cough, and altered sensorium. He had recently traveled to a hot spring with a group that included his wife, who also developed a fever and was diagnosed with COVID-19. On admission, results of urinary antigen tests for <italic>L. pneumophila</italic> and <italic>S. pneumoniae</italic> were positive, a SARS-CoV-2 nucleic acid amplification test was positive, and sputum culture yielded <italic>S. pneumoniae</italic>. Chest computed tomography revealed multifocal bilateral ground-glass opacities, small bilateral pleural effusions, and relatively well-defined right middle-lobe consolidation with air bronchograms in a peribronchovascular distribution. These microbiological and radiological findings supported a suspected triple co-infection rather than COVID-19 alone. Treatment with remdesivir, ceftriaxone, and levofloxacin was initiated, and the patient’s condition improved, with better oxygenation and decreased inflammatory markers. Remdesivir and ceftriaxone were discontinued after 5 days, whereas levofloxacin was continued for 14 days. Follow-up imaging revealed marked improvement, and the patient was discharged. Public health investigations did not detect <italic>Legionella</italic> at the hot-spring facility or identify any additional linked cases. This case highlights the importance of prompt pathogen-directed evaluation when COVID-19 pneumonia is accompanied by a relevant exposure history, host risk factors, and atypical imaging findings.</p>
</abstract>
<kwd-group>
<kwd>COVID-19</kwd>
<kwd>Legionnaires’ disease</kwd>
<kwd>
<italic>Streptococcus pneumoniae</italic>
</kwd>
<kwd>co-infection</kwd>
<kwd>case report</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p id="p-1">Bacterial co-infection in patients with coronavirus disease 2019 (COVID-19) can complicate diagnosis and management because of overlapping clinical manifestations, laboratory abnormalities, and chest imaging findings among pathogens [<xref ref-type="bibr" rid="B1">1</xref>]. Although pneumonia associated with COVID-19 and multiple bacterial pathogens, including <italic>Legionella</italic>, has rarely been reported, such cases may follow a severe clinical course [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>]. Cases with more than one pathogen may have an atypical presentation, and failure to recognize a treatable bacterial infection may delay appropriate therapy.</p>
<p id="p-2">We report a case of suspected triple co-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), <italic>Legionella pneumophila</italic> (<italic>L. pneumophila</italic>), and <italic>Streptococcus pneumoniae</italic> (<italic>S. pneumoniae</italic>) that developed after domestic travel to a hot spring in Japan in a patient with a history of splenectomy. This case underscores the importance of considering <italic>L. pneumophila</italic> involvement and other treatable bacterial co-infections when COVID-19 pneumonia is accompanied by recent hot-spring exposure, host risk factors, and atypical imaging findings. Careful exposure history taking and appropriate pathogen-directed testing are essential for identifying treatable co-infections, guiding timely empirical therapy, and facilitating subsequent antimicrobial adjustment or de-escalation [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>].</p>
</sec>
<sec id="s2">
<title>Timeline</title>
<p id="p-3">The patient was in his usual state of health before a 2-day hot-spring trip. After returning home, his wife developed fever first, followed by the patient the next day. Both were diagnosed with COVID-19 at a local clinic, and the patient was transported to our hospital after a worsening productive cough and altered sensorium. Subsequent hospital course, antimicrobial treatments, and laboratory results are summarized in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p>
<fig id="fig1" position="float">
<label>Figure 1</label>
<caption>
<p id="fig1-p-1">
<bold>Clinical course and chest radiographs of a patient with pneumonia.</bold> (<bold>A</bold>) Clinical course showing changes in peripheral oxygen saturation, white blood cell count, and C-reactive protein level after initiation of remdesivir, ceftriaxone, and levofloxacin. (<bold>B</bold>) Serial chest radiographs showing gradual improvement of pulmonary infiltrates. CRP: C-reactive protein; CTRX: ceftriaxone; LVFX: levofloxacin; SpO<sub>2</sub>: peripheral oxygen saturation; WBC: white blood cell count.</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="em-07-1001424-g001.tif" />
</fig>
</sec>
<sec id="s3">
<title>Narrative</title>
<p id="p-4">A man in his 70s was admitted to our hospital with fever, worsening productive cough, and altered sensorium. His medical history was notable for esophageal cancer treated with subtotal esophagectomy, followed by reconstruction and concomitant splenectomy 10 years prior to presentation. He had no history of smoking, consumed alcohol daily, and had no known drug allergies. He was not currently receiving corticosteroids, immunosuppressive agents, or anticancer therapy. He was independent in activities of daily living, had previously received pneumococcal vaccination, but had not been vaccinated against COVID-19.</p>
<p id="p-5">Several days before admission, he traveled to a hot spring for 2 days with a group of nine people, including his wife. After returning home, his wife developed fever, and he developed fever the following day. After being diagnosed with COVID-19 at a local clinic, both were managed conservatively with antipyretics. His productive cough subsequently worsened, and he developed altered sensorium that warranted emergency transport by ambulance to our hospital.</p>
<p id="p-6">On admission, his body temperature was 38.3°C, blood pressure was 130/60 mmHg, pulse rate was 72 beats/min, respiratory rate was 18 breaths/min, and oxygen saturation was 90% on room air. The patient was mildly confused, with a Glasgow Coma Scale score of 14 (E4V4M6). Physical examination revealed coarse crackles in the right lung. He had cough, sputum production, anorexia, and malaise, but no headache, chills, sore throat, abdominal pain, diarrhea, or myalgia.</p>
</sec>
<sec id="s4">
<title>Diagnostics</title>
<sec id="t4-1">
<title>Laboratory diagnosis</title>
<p id="p-7">Laboratory tests showed leukocytosis (white blood cell count, 13,900/μL) with neutrophil predominance, an elevated C-reactive protein level (23.6 mg/dL), hyponatremia (133 mEq/L), and hypoalbuminemia (2.5 g/dL). Total bilirubin and liver enzyme levels were within normal limits, as was renal function. Urinalysis and urine culture were unremarkable. Urinary antigen tests for <italic>L. pneumophila</italic> serogroup 1 and <italic>S. pneumoniae</italic> were positive. These tests were performed using the ImmunoCatch<sup>®</sup> Legionella (product code E-ET02) and ImmunoCatch<sup>®</sup> Pneumococcus kits (product code E-ET04), respectively (Eiken Chemical Co., Ltd., Tokyo, Japan), both of which are immunochromatographic assays.</p>
<p id="p-8">SARS-CoV-2 infection was confirmed by nucleic acid amplification testing on admission. Additional in-house real-time reverse transcription polymerase chain reaction testing performed on hospital day 3 using a QuantStudio 5 system (model A28134, 96-well, 0.2 mL; Thermo Fisher Scientific) with TaqMan™ Fast Virus 1-Step Master Mix (product No. 4444434; Thermo Fisher Scientific), Primer/Probe N2 (2019-nCoV) (product No. XD0008; Takara Bio Inc.), and a custom <italic>S</italic>-gene primer/probe set (Thermo Fisher Scientific) yielded cycle threshold values of 21.52 for the <italic>N2</italic> gene and 22.71 for the <italic>S</italic> gene, consistent with a high SARS-CoV-2 RNA burden. Mutation screening using TaqPath™ 1-Step RT-qPCR Master Mix, CG (product No. A15299; Thermo Fisher Scientific) and the TaqMan™ SARS-CoV-2 Mutation Panel (product No. A49785; Thermo Fisher Scientific) on the same platform detected the G339D and L452R mutations. According to the institutional testing algorithm in use at that time, the G339D-positive pattern was interpreted as being consistent with an Omicron variant.</p>
<p id="p-9">Gram staining of purulent sputum showed abundant Gram-positive cocci (4+), and sputum culture yielded <italic>S. pneumoniae</italic>, including both mucoid and non-mucoid morphotypes (2+ each). Species identification and antimicrobial susceptibility testing of the sputum isolate were performed using the RAISUS ANY automated microbiology system (model RAISUS ANY; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) with an RSCP2 identification and susceptibility plate (product No. 04135; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan). Blood cultures were negative.</p>
<p id="p-10">Chest computed tomography (CT) showed multifocal bilateral ground-glass opacities with a nonsegmental distribution, predominantly in the peripheral and subpleural lungs (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Superimposed on these opacities, a relatively well-defined area of consolidation with air bronchograms was observed in the right middle lobe in a peribronchovascular distribution with an adjacent faint reticular opacity. Furthermore, trace bilateral pleural effusion was observed. No significant mediastinal or hilar lymphadenopathy was observed.</p>
<fig id="fig2" position="float">
<label>Figure 2</label>
<caption>
<p id="fig2-p-1">
<bold>Chest computed tomography on admission.</bold> (<bold>A–C</bold>) Multifocal bilateral ground-glass opacities are distributed predominantly in the peripheral and subpleural lung fields. (<bold>D, E</bold>) A relatively well-defined consolidation with air bronchograms is present in the right middle lobe in a peribronchovascular distribution, accompanied by adjacent faint ground-glass and reticular opacities. (<bold>F</bold>) A small subpleural band-like opacity is present in the left lower lobe, with trace bilateral pleural effusions.</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="em-07-1001424-g002.tif" />
</fig>
<p id="p-11">Taken together, these microbiological and radiological findings supported the diagnosis of suspected triple co-infection involving SARS-CoV-2, <italic>L. pneumophila</italic>, and <italic>S. pneumoniae</italic>.</p>
</sec>
<sec id="t4-2">
<title>Therapeutic intervention and follow-up</title>
<p id="p-12">Treatment was initiated with remdesivir (200 mg IV on day 1 followed by 100 mg IV once daily on days 2–5), ceftriaxone (2 g IV once daily), and levofloxacin (500 mg PO once daily). The patient responded well, with improvement in oxygenation, radiographic abnormalities, and inflammatory markers. After antimicrobial susceptibility testing confirmed that the pneumococcal isolates were susceptible to ceftriaxone, ceftriaxone was discontinued after 5 days, whereas levofloxacin was continued for a total of 14 days. The patient was discharged following clinical improvement.</p>
<p id="p-13">Follow-up imaging showed regression of the right middle-lobe consolidation to a faint residual opacity, with near-complete resolution of the scattered ground-glass opacities. Subsequent investigations by the local public health authority, including sampling from four bathing areas at the hot-spring facility, did not detect <italic>Legionella</italic>. No additional cases were identified among the travel group or other facility users; moreover, no obvious alternative environmental source was found. Therefore, the case appeared sporadic, and the source of infection remained unidentified.</p>
</sec>
</sec>
<sec id="s5">
<title>Patient perspective</title>
<p id="p-14">At an outpatient follow-up visit after recovery, the patient was informed of the clinical course and favorable outcome. He understood that sharing the details of his case could be educational for clinicians, and provided written informed consent for publication.</p>
</sec>
<sec id="s6">
<title>Discussion</title>
<p id="p-15">This case highlights the difficulty in diagnosing pneumonia in patients with COVID-19 when more than one pathogen is involved. Although bacterial co-infection at the time of COVID-19 presentation is relatively uncommon, treatable bacterial pneumonia may be overlooked if all clinicoradiological findings are attributed solely to SARS-CoV-2 [<xref ref-type="bibr" rid="B1">1</xref>]. In this case, neutrophilic leukocytosis, productive cough, focal consolidation, marked inflammation, positive pneumococcal and <italic>L. pneumophila</italic> urinary antigen tests, growth of <italic>S. pneumoniae</italic> in sputum culture, and recent hot-spring exposure supported a suspected triple co-infection rather than COVID-19 alone.</p>
<p id="p-16">Several clinical features further supported suspected <italic>L. pneumophila</italic> infection. Current guidance recommends testing for Legionnaires’ disease in patients with pneumonia who have severe disease or overnight travel during the incubation period; moreover, the recommendations include combining urinary antigen testing with lower respiratory tract culture or molecular testing when Legionnaires’ disease is suspected [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>]. Hot-spring exposure is an important epidemiological clue because hot-spring bath water has been molecularly confirmed as the source of infection in a sporadic case of <italic>L. pneumophila</italic> pneumonia in Japan [<xref ref-type="bibr" rid="B8">8</xref>]. In addition, a relatively well-defined peribronchovascular consolidation with ground-glass opacities constitutes a characteristic CT pattern that is more frequent in <italic>L. pneumophila</italic> pneumonia than in pneumococcal pneumonia [<xref ref-type="bibr" rid="B9">9</xref>]. Urinary antigen testing for <italic>Legionella</italic> has high specificity; the reported pooled sensitivity and specificity were 79% and 100% overall and 86% and 100% for <italic>L. pneumophila</italic> serogroup 1, respectively [<xref ref-type="bibr" rid="B10">10</xref>]. Although respiratory culture or molecular testing for <italic>Legionella</italic> was unavailable, the positive urinary antigen result, when interpreted together with the exposure history, clinical features, and CT pattern, supported concomitant legionellosis. Persistent antigen excretion after a previous infection was unlikely because the patient had no known history of prior legionellosis [<xref ref-type="bibr" rid="B11">11</xref>]. Incidental false-positive results and pseudoepidemics have been reported [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>]. Pontiac fever was also considered but was less consistent with this patient’s radiographic pneumonia, hypoxemia, and focal consolidation [<xref ref-type="bibr" rid="B14">14</xref>].</p>
<p id="p-17">The timing of symptom onset was compatible with the possible acquisition of all three pathogens around the time of hot-spring travel. The reported incubation periods are a mean of 2.6 days for SARS-CoV-2 Omicron infection, 2–14 days for Legionnaires’ disease, and 1–3 days for pneumococcal pneumonia; the low cycle threshold values on hospital day 3 were consistent with a high viral RNA burden and recent active SARS-CoV-2 infection [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>].</p>
<p id="p-18">The clinical presentation may have reflected overlapping but largely independent risk factors: lack of COVID-19 vaccination, recent hot-spring exposure, and prior splenectomy. SARS-CoV-2-related airway epithelial injury and impaired mucociliary clearance may have compromised local airway defenses and facilitated bacterial co-infection [<xref ref-type="bibr" rid="B17">17</xref>]. Concomitant <italic>L. pneumophila</italic> and <italic>S. pneumoniae</italic> infections occur rarely and have mainly been described in case reports [<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. Thus, this case is best interpreted as involving overlapping risks and possible sequential infections rather than a proven pathogen–pathogen interaction.</p>
<p id="p-19">The history of splenectomy supports the clinical significance of pneumococcal infection but does not directly explain susceptibility to SARS-CoV-2 or <italic>Legionella</italic>. This is because asplenia mainly predisposes patients to infections that are caused by encapsulated bacteria, especially <italic>S. pneumoniae</italic>, through impaired splenic clearance and polysaccharide antigen responses [<xref ref-type="bibr" rid="B20">20</xref>]. However, prior pneumococcal vaccination does not eliminate this residual risk [<xref ref-type="bibr" rid="B21">21</xref>]. Unlike the fatal case reported by Fukuda et al., in which <italic>L. pneumophila</italic> and <italic>S. pneumoniae</italic> co-infection developed during dexamethasone and baricitinib therapy for COVID-19 [<xref ref-type="bibr" rid="B3">3</xref>], our patient had a post-splenectomy host risk rather than pharmacological immunosuppression, and improved with early pathogen-directed therapy.</p>
<p id="p-20">This case underscores the need for early microbiological evaluation when bacterial co-infection is suspected in patients with COVID-19 pneumonia. In such cases, multiplex molecular panels may complement exposure-directed testing by facilitating the simultaneous detection of additional respiratory pathogens [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B22">22</xref>].</p>
</sec>
<sec id="s7">
<title>Conclusions</title>
<p id="p-21">We report a case of suspected triple co-infection involving SARS-CoV-2, <italic>L. pneumophila</italic>, and <italic>S. pneumoniae</italic> after hot-spring travel in a post-splenectomy patient. Clinicians should consider <italic>Legionella</italic> infection when COVID-19 pneumonia is accompanied by recent hot-spring or aerosolized water exposure, atypical imaging findings, or host risk factors, and should promptly evaluate treatable bacterial pathogens.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>COVID-19</term>
<def>
<p>coronavirus disease 2019</p>
</def>
</def-item>
<def-item>
<term>CT</term>
<def>
<p>computed tomography</p>
</def>
</def-item>
<def-item>
<term>
<italic>L. pneumophila</italic>
</term>
<def>
<p>
<italic>Legionella pneumophila</italic>
</p>
</def>
</def-item>
<def-item>
<term>
<italic>S. pneumoniae</italic>
</term>
<def>
<p>
<italic>Streptococcus pneumoniae</italic>
</p>
</def>
</def-item>
<def-item>
<term>SARS-CoV-2</term>
<def>
<p>severe acute respiratory syndrome coronavirus 2</p>
</def>
</def-item>
</def-list>
</glossary>
<sec id="s8">
<title>Declarations</title>
<sec id="t-8-1">
<title>Acknowledgments</title>
<p>We would like to thank Editage (<uri xlink:href="http://www.editage.jp">www.editage.jp</uri>) for English language editing.</p>
</sec>
<sec id="t-8-2">
<title>Author contributions</title>
<p>RH: Writing—original draft. HT: Conceptualization, Methodology, Investigation, Data curation, Visualization, Project administration, Writing—original draft. TY: Writing—review &amp; editing. KT: Writing—review &amp; editing. KF: Writing—review &amp; editing. YS: Writing—review &amp; editing. HN: Writing—review &amp; editing. NT: Writing—review &amp; editing. MTK: Writing—review &amp; editing. SO: Writing—review &amp; editing. MM: Writing—review &amp; editing. MS: Writing—review &amp; editing. All authors read and approved the submitted version.</p>
</sec>
<sec id="t-8-3" sec-type="COI-statement">
<title>Conflicts of interest</title>
<p>The authors declare that they have no conflicts of interest.</p>
</sec>
<sec id="t-8-4">
<title>Ethical approval</title>
<p>This case report was conducted in accordance with the Declaration of Helsinki. Ethical approval was not required for this single case report according to institutional policy because it describes routine clinical care.</p>
</sec>
<sec id="t-8-5">
<title>Consent to participate</title>
<p>Written informed consent to participate was obtained from the patient.</p>
</sec>
<sec id="t-8-6">
<title>Consent to publication</title>
<p>Written informed consent was obtained from the patient for publication of this manuscript and the accompanying images.</p>
</sec>
<sec id="t-8-7" sec-type="data-availability">
<title>Availability of data and materials</title>
<p>The data supporting the findings of this case report are available from the corresponding author upon reasonable request, within the limits of patient privacy and confidentiality.</p>
</sec>
<sec id="t-8-8">
<title>Funding</title>
<p>Not applicable.</p>
</sec>
<sec id="t-8-9">
<title>Copyright</title>
<p>© The Author(s) 2026.</p>
</sec>
</sec>
<sec id="s9">
<title>Publisher’s note</title>
<p>Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.</p>
</sec>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langford</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>So</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Raybardhan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Westwood</surname>
<given-names>D</given-names>
</name>
<name>
<surname>MacFadden</surname>
<given-names>DR</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis</article-title>
<source>Clin Microbiol Infect</source>
<year iso-8601-date="2020">2020</year>
<volume>26</volume>
<fpage>1622</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmi.2020.07.016</pub-id>
<pub-id pub-id-type="pmid">32711058</pub-id>
<pub-id pub-id-type="pmcid">PMC7832079</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riccò</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ferraro</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Peruzzi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zaniboni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ranzieri</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2–Legionella Co-Infections: A Systematic Review and Meta-Analysis (2020–2021)</article-title>
<source>Microorganisms</source>
<year iso-8601-date="2022">2022</year>
<volume>10</volume>
<elocation-id>499</elocation-id>
<pub-id pub-id-type="doi">10.3390/microorganisms10030499</pub-id>
<pub-id pub-id-type="pmid">35336074</pub-id>
<pub-id pub-id-type="pmcid">PMC8951730</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fukuda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakahira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shiraishi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Atagi</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Concomitant Legionella pneumophila and Streptococcus pneumoniae Infections With Refractory Necrotizing Pneumonia in a Patient Receiving Immunosuppressive Therapy for COVID-19</article-title>
<source>Cureus</source>
<year iso-8601-date="2025">2025</year>
<volume>17</volume>
<elocation-id>e92531</elocation-id>
<pub-id pub-id-type="doi">10.7759/cureus.92531</pub-id>
<pub-id pub-id-type="pmid">41111643</pub-id>
<pub-id pub-id-type="pmcid">PMC12535418</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manolescu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Stoicescu</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Fildan</surname>
<given-names>AP</given-names>
</name>
</person-group>
<article-title>Editorial: Advances in the diagnosis and management of infectious diseases</article-title>
<source>Front Cell Infect Microbiol</source>
<year iso-8601-date="2026">2026</year>
<volume>15</volume>
<elocation-id>1765521</elocation-id>
<pub-id pub-id-type="doi">10.3389/fcimb.2025.1765521</pub-id>
<pub-id pub-id-type="pmid">41567999</pub-id>
<pub-id pub-id-type="pmcid">PMC12815824</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Abideen</surname>
<given-names>ZU</given-names>
</name>
<name>
<surname>Azmat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Irfan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Anjum</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dirie</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Impact of COVID-19 on the prevalence of multi-drug-resistant bacteria: a literature review and meta-analysis</article-title>
<source>Antonie Leeuwenhoek</source>
<year iso-8601-date="2025">2025</year>
<volume>118</volume>
<elocation-id>165</elocation-id>
<pub-id pub-id-type="doi">10.1007/s10482-025-02181-x</pub-id>
<pub-id pub-id-type="pmid">41045404</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Metlay</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Waterer</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Anzueto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brozek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Crothers</surname>
<given-names>K</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America</article-title>
<source>Am J Respir Crit Care Med</source>
<year iso-8601-date="2019">2019</year>
<volume>200</volume>
<fpage>e45</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.201908-1581st</pub-id>
<pub-id pub-id-type="pmid">31573350</pub-id>
<pub-id pub-id-type="pmcid">PMC6812437</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="web">
<article-title>Clinical guidance for <italic>Legionella</italic> infections [Internet]</article-title>
<comment>Atlanta (GA): Centers for Disease Control and Prevention; c2025 [cited 2026 May 17]. Available from: <uri xlink:href="https://www.cdc.gov/legionella/hcp/clinical-guidance/index.html">https://www.cdc.gov/legionella/hcp/clinical-guidance/index.html</uri></comment>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jitsurong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shiota</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maruta</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yabuuchi</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Molecular Determination of Infection Source of a Sporadic <italic>Legionella</italic> Pneumonia Case Associated with a Hot Spring Bath</article-title>
<source>Microbiol Immunol</source>
<year iso-8601-date="1997">1997</year>
<volume>41</volume>
<fpage>197</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1111/j.1348-0421.1997.tb01190.x</pub-id>
<pub-id pub-id-type="pmid">9130230</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shinomiya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Niimi</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Characteristic computed tomography features of mild-to-moderate Legionella pneumonia: evaluation of a known pattern and identification of a novel indicator</article-title>
<source>BMC Pulm Med</source>
<year iso-8601-date="2026">2026</year>
<volume>26</volume>
<elocation-id>173</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12890-026-04210-5</pub-id>
<pub-id pub-id-type="pmid">41795078</pub-id>
<pub-id pub-id-type="pmcid">PMC13081545</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawasaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Murata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yasuo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>K</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Diagnostic accuracy of urinary antigen tests for legionellosis: A systematic review and meta-analysis</article-title>
<source>Respir Investig</source>
<year iso-8601-date="2022">2022</year>
<volume>60</volume>
<fpage>205</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1016/j.resinv.2021.11.011</pub-id>
<pub-id pub-id-type="pmid">34972680</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sopena</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sabrià</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pedro-Botet</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Reynaga</surname>
<given-names>E</given-names>
</name>
<name>
<surname>García-Núñez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Domínguez</surname>
<given-names>J</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Factors Related to Persistence of Legionella Urinary Antigen Excretion in Patients with Legionnaires’ Disease</article-title>
<source>Eur J Clin Microbiol Infect Dis</source>
<year iso-8601-date="2002">2002</year>
<volume>21</volume>
<fpage>845</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1007/s10096-002-0839-5</pub-id>
<pub-id pub-id-type="pmid">12525918</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Como</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Moffa</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Bhanot</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Kuzyck</surname>
<given-names>J</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Potential false-positive urine Legionella enzyme immunoassay test results</article-title>
<source>Eur J Clin Microbiol Infect Dis</source>
<year iso-8601-date="2019">2019</year>
<volume>38</volume>
<fpage>1377</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1007/s10096-019-03575-2</pub-id>
<pub-id pub-id-type="pmid">31119574</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rota</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Fontana</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Montaño-Remacha</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Scaturro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Caporali</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Vullo</surname>
<given-names>V</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Legionnaires’ Disease Pseudoepidemic Due to Falsely Positive Urine Antigen Test Results</article-title>
<source>J Clin Microbiol</source>
<year iso-8601-date="2014">2014</year>
<volume>52</volume>
<fpage>2279</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1128/jcm.00493-14</pub-id>
<pub-id pub-id-type="pmid">24719437</pub-id>
<pub-id pub-id-type="pmcid">PMC4042736</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burnsed</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Hicks</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Smithee</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Fields</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Pascoe</surname>
<given-names>N</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>A Large, Travel-Associated Outbreak of Legionellosis among Hotel Guests: Utility of the Urine Antigen Assay in Confirming Pontiac Fever</article-title>
<source>Clin Infect Dis</source>
<year iso-8601-date="2007">2007</year>
<volume>44</volume>
<fpage>222</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1086/510387</pub-id>
<pub-id pub-id-type="pmid">17173221</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 Incubation Period during the Omicron BA.5–Dominant Period in Japan</article-title>
<source>Emerg Infect Dis</source>
<year iso-8601-date="2023">2023</year>
<volume>29</volume>
<fpage>595</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.3201/eid2903.221360</pub-id>
<pub-id pub-id-type="pmid">36787734</pub-id>
<pub-id pub-id-type="pmcid">PMC9973685</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Gierke</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wodi</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Pneumococcal disease</article-title>
<person-group person-group-type="editor">
<name>
<surname>Hall</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wodi</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Hamborsky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Morelli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Schillie</surname>
<given-names>S</given-names>
</name>
</person-group>
<source>Epidemiology and prevention of vaccine-preventable diseases</source>
<edition>14th ed</edition>
<publisher-loc>Washington (DC)</publisher-loc>
<publisher-name>Public Health Foundation</publisher-name>
<year iso-8601-date="2021">2021</year>
<comment>pp. 255–74.</comment>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinot</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hubert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Melo</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Lazarini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bruel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>N</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance</article-title>
<source>Nat Commun</source>
<year iso-8601-date="2021">2021</year>
<volume>12</volume>
<elocation-id>4354</elocation-id>
<pub-id pub-id-type="doi">10.1038/s41467-021-24521-x</pub-id>
<pub-id pub-id-type="pmid">34272374</pub-id>
<pub-id pub-id-type="pmcid">PMC8285531</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orsini</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Frawley</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Gawlak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gooch</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Escovar</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Severe Sepsis With Septic Shock as a Consequence of a Severe Community-Acquired Pneumonia Resulting From a Combined Legionella pneumophila and Streptococcus pneumoniae Infection</article-title>
<source>Cureus</source>
<year iso-8601-date="2020">2020</year>
<volume>12</volume>
<elocation-id>e10966</elocation-id>
<pub-id pub-id-type="doi">10.7759/cureus.10966</pub-id>
<pub-id pub-id-type="pmid">33094037</pub-id>
<pub-id pub-id-type="pmcid">PMC7571607</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arif</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Community-acquired Pneumonia Secondary to Legionella pneumophila and Streptococcus pneumoniae: A Rare Co-infection</article-title>
<source>Cureus</source>
<year iso-8601-date="2019">2019</year>
<volume>11</volume>
<elocation-id>e4080</elocation-id>
<pub-id pub-id-type="doi">10.7759/cureus.4080</pub-id>
<pub-id pub-id-type="pmid">31019858</pub-id>
<pub-id pub-id-type="pmcid">PMC6467430</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenti</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Luu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Carsetti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Osier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ogwang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nnodu</surname>
<given-names>OE</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Asplenia and spleen hypofunction</article-title>
<source>Nat Rev Dis Primers</source>
<year iso-8601-date="2022">2022</year>
<volume>8</volume>
<elocation-id>71</elocation-id>
<pub-id pub-id-type="doi">10.1038/s41572-022-00399-x</pub-id>
<pub-id pub-id-type="pmid">36329079</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pilishvili</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Farrar</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Leidner</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Gierke</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>N</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023</article-title>
<source>MMWR Recomm Rep</source>
<year iso-8601-date="2023">2023</year>
<volume>72</volume>
<fpage>1</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.15585/mmwr.rr7203a1</pub-id>
<pub-id pub-id-type="pmid">37669242</pub-id>
<pub-id pub-id-type="pmcid">PMC10495181</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El</surname>
<given-names>Kholy AA</given-names>
</name>
<name>
<surname>Mostafa</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Soliman</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>El-Sherbini</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Ismail</surname>
<given-names>RI</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>The use of multiplex PCR for the diagnosis of viral severe acute respiratory infection in children: a high rate of co-detection during the winter season</article-title>
<source>Eur J Clin Microbiol Infect Dis</source>
<year iso-8601-date="2016">2016</year>
<volume>35</volume>
<fpage>1607</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1007/s10096-016-2698-5</pub-id>
<pub-id pub-id-type="pmid">27287764</pub-id>
<pub-id pub-id-type="pmcid">PMC7088036</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>